Bivalirudin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 250 mg
Reference Brands: Angiomax (USA)
Category:
Anaesthetics
Bivalirudin is available in Injection
and strengths such as 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bivalirudin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bivalirudin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Bivalirudin is a direct thrombin inhibitor widely used in the management of patients undergoing percutaneous coronary intervention (PCI), particularly in cases of acute myocardial infarction. It plays a critical role in preventing thrombus formation during interventional cardiac procedures by providing rapid, predictable, and controllable anticoagulation. In addition to its established use in PCI, bivalirudin has broader clinical applications, including the management of thromboembolic disorders, cardiopulmonary bypass procedures, and extracorporeal membrane oxygenation, where precise anticoagulant control is essential.
Chemically, bivalirudin is a short, synthetic peptide derived from hirudin, a naturally occurring anticoagulant found in the saliva of the medicinal leech Hirudo medicinalis. It acts by directly and reversibly binding to thrombin, inhibiting both circulating and clot-bound thrombin, as well as thrombin-mediated platelet activation and aggregation. Unlike indirect thrombin inhibitors such as heparin, bivalirudin does not require antithrombin as a cofactor, does not bind to plasma proteins or red blood cells, and does not activate platelets.
Bivalirudin has a rapid onset of action and a short half-life, resulting in a predictable antithrombotic response. Importantly, it carries no risk of heparin-induced thrombocytopenia, making it a reliable alternative to heparin in high-risk patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing